nach oben

Erschienen in:

17.01.2020 | Original Article

Association between radiotherapy-induced alteration of programmed death ligand 1 and survival in patients with uterine cervical cancer undergoing preoperative radiotherapy

verfasst von: Takaaki Tsuchiya, Masanori Someya, Yu Takada, Tomokazu Hasegawa, Mio Kitagawa, Yuki Fukushima, Toshio Gocho, Masakazu Hori, Kensei Nakata, Yoshihiko Hirohashi, Toshihiko Torigoe, Tsuyoshi Saito, Koh-ichi Sakata, MD PhD

Erschienen in: Strahlentherapie und Onkologie | Ausgabe 8/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To evaluate radiotherapy-induced changes in the expression of programmed death ligand 1 (PD-L1), programmed death 1 (PD-1), and human leukocyte antigen class I (HLA-1) in patients with uterine cervical cancer, as well as infiltration of CD8+ and Forkhead box P3+ (FoxP3+) T lymphocytes into tumor tissue and the prognostic value of these parameters.

Materials and methods

We performed immunohistochemical analysis of pre-radiotherapy biopsies and corresponding post-radiotherapy resected tissues in 104 uterine cervical cancer patients undergoing preoperative chemoradiotherapy or radiotherapy alone. We scored the expression of various proteins to distinguish positive from negative samples.

Results

PD-L1-expressing tumor cells (PD-L1 TC) increased significantly after chemoradiotherapy (p = 0.043). CD8+ T cell infiltration (p = 0.002) and FoxP3+ T cell infiltration (p = 0.003) decreased significantly after chemoradiotherapy. Expression of PD‑1, PD-L1-expressing immune cells (PD-L1 IC), and HLA‑1 did not change after chemoradiotherapy. In biopsy specimens obtained before chemoradiotherapy or radiotherapy, greater infiltration of CD8+ T cells (p = 0.001) and FoxP3+ T cells (p = 0.003) were significant predictors of better overall survival (OS). In surgical specimens obtained after chemoradiotherapy or radiotherapy, greater infiltration of PD-L1 TC was the only significant predictor of better OS (p < 0.001) and was related to a significantly lower probability of out-of-field recurrence (p = 0.005).

Conclusion

Chemoradiotherapy induced an immunologic shift that increased PD-L1 TC. Chemoradiotherapy has immunological effects that can influence the results of treatment for uterine cervical cancer.

Nur mit Berechtigung zugänglich

Zitvogel L, Apetoh L, Ghiringhelli F, Kroemer G (2008) Immunological aspects of cancer chemotherapy. Nat Rev Immunol 8:59–73. https://doi.org/10.1038/nri2216 CrossRefPubMed

Formenti SC, Demaria S (2009) Systemic effects of local radiotherapy. Lancet Oncol 10:718–726. https://doi.org/10.1016/S1470-2045(09)70082-8 CrossRefPubMedPubMedCentral

Schmidt MA, Förtsch C, Schmidt M, Rau TT, Fietkau R, Distel LV (2012) Circulating regulatory T cells of cancer patients receiving radiochemotherapy may be useful to individualize cancer treatment. Radiother Oncol 104:131–138. https://doi.org/10.1016/j.radonc.2012.05.003 CrossRefPubMed

Schaue D, Comin-Anduix B, Ribas A, Zhang L, Goodglick L, Sayre JW, Debucquoy A, Haustermans K, McBride WH (2008) T‑cell responses to survivin in cancer patients undergoing radiation therapy. Clin Cancer Res 14:4883–4890. https://doi.org/10.1158/1078-0432.CCR-07-4462 CrossRefPubMedPubMedCentral

Deng L, Liang H, Burnette B, Beckett M, Darga T, Weichselbaum RR, Fu YX (2014) Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. J Clin Invest 124:687–695. https://doi.org/10.1172/JCI67313 CrossRefPubMedPubMedCentral

Dovedi SJ, Adlard AL, Lipowska-Bhalla G, McKenna C, Jones S, Cheadle EJ, Stratford IJ, Poon E, Morrow M, Stewart R, Jones H, Wilkinson RW, Honeychurch J, Illidge TM (2014) Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade. Cancer Res 74:5458–5468. https://doi.org/10.1158/0008-5472.CAN-14-1258 CrossRefPubMed

de Biasi AR, Villena-Vargas J, Adusumilli PS (2014) Cisplatin-induced antitumor immunomodulation: a review of preclinical and clinical evidence. Clin Cancer Res 20:5384–5391. https://doi.org/10.1158/1078-0432.CCR-14-1298 CrossRefPubMedPubMedCentral

Takada Y, Someya M, Matsumoto Y, Satoh M, Nakata K, Hori M, Saito M, Hirokawa N, Tateoka K, Teramoto M, Saito T, Hasegawa T, Sakata KI (2016) Influence of Ku86 and XRCC4 expression in uterine cervical cancer on the response to preoperative radiotherapy. Med Mol Morphol 49:210–216. https://doi.org/10.1007/s00795-016-0136-5 CrossRefPubMed

Topalian SL, Taube JM, Anders RA, Pardoll DM (2016) Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat Rev Cancer 16:275–287. https://doi.org/10.1038/nrc.2016.36 CrossRefPubMedPubMedCentral

10.

Fontenot JD, Gavin MA, Rudensky AY (2017) Pillars Article: Foxp3 Programs the Development and Function of CD4+CD25+ Regulatory T Cells. J Immunol 198:986–992. https://doi.org/10.1038/ni904 CrossRefPubMed

11.

Sakata K, Matsumoto Y, Tauchi H, Satoh M, Oouchi A, Nagakura H, Koito K, Hosoi Y, Suzuki N, Komatsu K, Hareyama M (2001) Expression of genes involved in repair of DNA double-strand breaks in normal and tumor tissues. Int J Radiat Oncol Biol Phys 49:161–167. https://doi.org/10.1016/S0360-3016(00)01352-3 CrossRefPubMed

12.

Kim HR, Ha SJ, Hong MH, Heo SJ, Koh YW, Choi EC, Kim EK, Pyo KH, Jung I, Seo D, Choi J, Cho BC, Yoon SO (2016) PD-L1 expression on immune cells, but not on tumor cells, is a favorable prognostic factor for head and neck cancer patients. Sci Rep 6:36956. https://doi.org/10.1038/srep36956 CrossRefPubMedPubMedCentral

13.

Fehrenbacher L, Spira A, Ballinger M, Kowanetz M, Vansteenkiste J, Mazieres J, Park K, Smith D, Artal-Cortes A, Lewanski C, Braiteh F, Waterkamp D, He P, Zou W, Chen DS, Yi J, Sandler A, Rittmeyer A, Group PS (2016) Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet 387:1837–1846. https://doi.org/10.1016/S0140-6736(16)00587-0 CrossRefPubMed

14.

Ventana Medical Systems, Inc. (2016) http://www.accessdata.fda.gov/cdrh_docs/pdf16/P160002c.pdf. Accessed 10 June 2019

15.

Kanda Y (2013) Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant 48:452–458. https://doi.org/10.1038/bmt.2012.244 CrossRefPubMed

16.

Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS, Sosman JA, McDermott DF, Powderly JD, Gettinger SN, Kohrt HE, Horn L, Lawrence DP, Rost S, Leabman M, Xiao Y, Mokatrin A, Koeppen H, Hegde PS, Mellman I, Chen DS, Hodi FS (2014) Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515:563–567. https://doi.org/10.1038/nature14011 CrossRefPubMedPubMedCentral

17.

Gubin MM, Zhang X, Schuster H, Caron E, Ward JP, Noguchi T, Ivanova Y, Hundal J, Arthur CD, Krebber WJ, Mulder GE, Toebes M, Vesely MD, Lam SS, Korman AJ, Allison JP, Freeman GJ, Sharpe AH, Pearce EL, Schumacher TN, Aebersold R, Rammensee HG, Melief CJ, Mardis ER, Gillanders WE, Artyomov MN, Schreiber RD (2014) Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature 515:577–581. https://doi.org/10.1038/nature13988 CrossRefPubMedPubMedCentral

18.

Xiao Y, Freeman GJ (2015) The microsatellite instable subset of colorectal cancer is a particularly good candidate for checkpoint blockade immunotherapy. Cancer Discov 5:16–18. https://doi.org/10.1158/2159-8290.CD-14-1397 CrossRefPubMedPubMedCentral

19.

Strickland KC, Howitt BE, Shukla SA, Rodig S, Ritterhouse LL, Liu JF, Garber JE, Chowdhury D, Wu CJ, D’Andrea AD, Matulonis UA, Konstantinopoulos PA (2016) Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer. Oncotarget 7:13587–13598. https://doi.org/10.18632/oncotarget.7277 CrossRefPubMedPubMedCentral

20.

Yadav M, Jhunjhunwala S, Phung QT, Lupardus P, Tanguay J, Bumbaca S, Franci C, Cheung TK, Fritsche J, Weinschenk T, Modrusan Z, Mellman I, Lill JR, Delamarre L (2014) Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing. Nature 515:572–576. https://doi.org/10.1038/nature14001 CrossRefPubMed

21.

Piersma SJ, Welters MJ, van der Hulst JM, Kloth JN, Kwappenberg KM, Trimbos BJ, Melief CJ, Hellebrekers BW, Fleuren GJ, Kenter GG, Offringa R, van der Burg SH (2008) Human papilloma virus specific T cells infiltrating cervical cancer and draining lymph nodes show remarkably frequent use of HLA-DQ and -DP as a restriction element. Int J Cancer 122:486–494. https://doi.org/10.1002/ijc.23162 CrossRefPubMed

22.

Sato H, Niimi A, Yasuhara T, Permata TBM, Hagiwara Y, Isono M, Nuryadi E, Sekine R, Oike T, Kakoti S, Yoshimoto Y, Held KD, Suzuki Y, Kono K, Miyagawa K, Nakano T, Shibata A (2017) DNA double-strand break repair pathway regulates PD-L1 expression in cancer cells. Nat Commun 8:1751. https://doi.org/10.1038/s41467-017-01883-9 CrossRefPubMedPubMedCentral

23.

Lim YJ, Koh J, Kim S, Jeon SR, Chie EK, Kim K, Kang GH, Han SW, Kim TY, Jeong SY, Park KJ, Wu HG (2017) Chemoradiation-induced alteration of programmed death-Ligand 1 and CD8. Int J Radiat Oncol Biol Phys 99:1216–1224. https://doi.org/10.1016/j.ijrobp.2017.07.004 CrossRefPubMed

24.

Badoual C, Hans S, Merillon N, Van Ryswick C, Ravel P, Benhamouda N, Levionnois E, Nizard M, Si-Mohamed A, Besnier N, Gey A, Rotem-Yehudar R, Pere H, Tran T, Guerin CL, Chauvat A, Dransart E, Alanio C, Albert S, Barry B, Sandoval F, Quintin-Colonna F, Bruneval P, Fridman WH, Lemoine FM, Oudard S, Johannes L, Olive D, Brasnu D, Tartour E (2013) PD-1-expressing tumor-infiltrating T cells are a favorable prognostic biomarker in HPV-associated head and neck cancer. Cancer Res 73:128–138. https://doi.org/10.1158/0008-5472.CAN-12-2606 CrossRefPubMed

25.

Piersma SJ, Jordanova ES, van Poelgeest MI, Kwappenberg KM, van der Hulst JM, Drijfhout JW, Melief CJ, Kenter GG, Fleuren GJ, Offringa R, van der Burg SH (2007) High number of intraepithelial CD8+ tumor-infiltrating lymphocytes is associated with the absence of lymph node metastases in patients with large early-stage cervical cancer. Cancer Res 67:354–361. https://doi.org/10.1158/0008-5472.CAN-06-3388 CrossRefPubMed

26.

Balermpas P, Martin D, Wieland U, Rave-Fränk M, Strebhardt K, Rödel C, Fokas E, Rödel F (2017) Human papilloma virus load and PD-1/PD-L1, CD8. OncoImmunology 6:e1288331. https://doi.org/10.1080/2162402X.2017.1288331 CrossRefPubMedPubMedCentral

27.

Taube JM, Anders RA, Young GD, Xu H, Sharma R, McMiller TL, Chen S, Klein AP, Pardoll DM, Topalian SL, Chen L (2012) Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med 4:127ra37. https://doi.org/10.1126/scitranslmed.3003689 CrossRefPubMedPubMedCentral

28.

Enwere EK, Kornaga EN, Dean M, Koulis TA, Phan T, Kalantarian M, Köbel M, Ghatage P, Magliocco AM, Lees-Miller SP, Doll CM (2017) Expression of PD-L1 and presence of CD8-positive T cells in pre-treatment specimens of locally advanced cervical cancer. Mod Pathol 30:577–586. https://doi.org/10.1038/modpathol.2016.221 CrossRefPubMed

29.

Fukushima Y, Someya M, Nakata K, Hori M, Kitagawa M, Hasegawa T, Tsuchiya T, Gocho T, Ikeda H, Hirohashi Y, Torigoe T, Sugita S, Himi T, Sakata KI (2018) Influence of PD-L1 expression in immune cells on the response to radiation therapy in patients with oropharyngeal squamous cell carcinoma. Radiother Oncol 129:409–414. https://doi.org/10.1016/j.radonc.2018.08.023 CrossRefPubMed

30.

Velcheti V, Schalper KA, Carvajal DE, Anagnostou VK, Syrigos KN, Sznol M, Herbst RS, Gettinger SN, Chen L, Rimm DL (2014) Programmed death ligand‑1 expression in non-small cell lung cancer. Lab Invest 94:107–116. https://doi.org/10.1038/labinvest.2013.130 CrossRefPubMed

31.

Rückert M, Deloch L, Fietkau R, Frey B, Hecht M, Gaipl US (2018) Immune modulatory effects of radiotherapy as basis for well-reasoned radioimmunotherapies. Strahlenther Onkol 194:509–519. https://doi.org/10.1007/s00066-018-1287-1 CrossRefPubMed

32.

Suzuki Y, Mimura K, Yoshimoto Y, Watanabe M, Ohkubo Y, Izawa S, Murata K, Fujii H, Nakano T, Kono K (2012) Immunogenic tumor cell death induced by chemoradiotherapy in patients with esophageal squamous cell carcinoma. Cancer Res 72:3967–3976. https://doi.org/10.1158/0008-5472.CAN-12-0851 CrossRefPubMed

33.

Derer A, Spiljar M, Bäumler M, Hecht M, Fietkau R, Frey B, Gaipl US (2016) Chemoradiation increases PD-L1 expression in certain melanoma and glioblastoma cells. Front Immunol 7:610. https://doi.org/10.3389/fimmu.2016.00610 CrossRefPubMedPubMedCentral

34.

Kunz P, Fellenberg J, Moskovszky L, Sápi Z, Krenacs T, Poeschl J, Lehner B, Szendrõi M, Ewerbeck V, Kinscherf R, Fritzsching B (2014) Osteosarcoma microenvironment: whole-slide imaging and optimized antigen detection overcome major limitations in immunohistochemical quantification. Plos One 9(3):e90727. https://doi.org/10.1371/journal.pone.0090727 CrossRefPubMedPubMedCentral

35.

McIntire PJ, Irshaid L, Liu Y, Chen Z, Menken F, Nowak E, Shin SJ, Ginter PS (2018) Hot spot and whole-tumor enumeration of CD8(+) tumor-infiltrating lymphocytes utilizing digital image analysis is prognostic in triple-negative breast cancer. Clin Breast Cancer 18:451–458. https://doi.org/10.1016/j.clbc.2018.04.019 CrossRefPubMed

Titel: Association between radiotherapy-induced alteration of programmed death ligand 1 and survival in patients with uterine cervical cancer undergoing preoperative radiotherapy
verfasst von: Takaaki Tsuchiya
Masanori Someya
Yu Takada
Tomokazu Hasegawa
Mio Kitagawa
Yuki Fukushima
Toshio Gocho
Masakazu Hori
Kensei Nakata
Yoshihiko Hirohashi
Toshihiko Torigoe
Tsuyoshi Saito
Koh-ichi Sakata, MD PhD
Publikationsdatum: 17.01.2020
Verlag: Springer Berlin Heidelberg
Erschienen in: Strahlentherapie und Onkologie / Ausgabe 8/2020
Print ISSN: 0179-7158
Elektronische ISSN: 1439-099X
DOI: https://doi.org/10.1007/s00066-019-01571-1

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Springer Medizin

Association between radiotherapy-induced alteration of programmed death ligand 1 and survival in patients with uterine cervical cancer undergoing preoperative radiotherapy

Abstract

Purpose

Materials and methods

Results

Conclusion

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Purpose

Materials and methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 8/2020

Low-dose radiotherapy for SARS-CoV-2 pneumonia

Zeitliche Abfolge der Androgendeprivation und externen Strahlenbehandlung beim lokal begrenzten Prostatakarzinom: eine randomisierte, kontrollierte Phase-III-Studie

Quality of teaching radiation oncology in Germany—where do we stand?

Zielvolumenreduktion durch 18F-FDG-PET/CT-basierte „involved field“ Bestrahlung beim fortgeschrittenen NSCLC möglicherweise neuer Standard: Ergebnisse der PET-Plan-Studie

Happy birthday, Klaus-Rüdiger! Heartfelt appreciation on the occasion of the 80th birthday of Professor Klaus-Rüdiger Trott

Induktionschemotherapie mit Cisplatin und Gemcitabin, gefolgt von Radiochemotherapie bei Nasopharynxkarzinomen

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie